The emerging technologies are beginning to emerge, at least into the higher echelons of the culture. First it was synthetic biology in the New Yorker, now the Singularity in the NY Times. Interestingly, the business section of the NYT. Which all goes to show that some of us have been right to look to savvy investors to raise the key questions – and, just perhaps, to persuade policymakers and cultural leaders of them.

The largest networking conference for European biotechs is hosted every summer by ERBI (acronyms tend to turn into names as they outgrow their original scope, and so it is with this one). The Cambridge BioPartnering Exchange. Participants were mainly UK-based, with a large number headquartered in and around Cambridge (where else, given the research, business, and cultural resources clustered on the banks of the Cam?). I had been invited to go along to chair a panel on emerging tech issues, and could hardly refuse. (Full disclosure: I am a Cambridge grad, so any excuse to visit home is appreciated.) And the Wellcome Trust set-up at Hinxton provides an excellent venue, and not only because of the ambient wifi (can anyone now run a serious professional event without it?).

A comment on the nature of the networking. I’m always interested in hanging out where worlds come together, and while this was a very biz-focused crowd it hosted many diversities – various internationals (especially Canadians, who were there in profusion), and a healthy cluster of CEOs, along with the biz dev types and the consultants who tend to pepper such gatherings. UKTI and consular tech people mingled with lawyers and a smattering of academics and networking leaders come to network their networks. My clutch of biz cards was I think representative: 5 out of 6 are on LinkedIn (mostly seriously, though a couple of people with two accounts and one actually with three – does that mean they are even more serious or less so?). Interestingly, almost all the LI people I connected with protect their own lists of connections. (I’ve never done that: love sharing old friends with new friends in our increasingly viral world.) And perhaps equally interestingly hardly anyone seemed to be on Twitter. Fiona Godsman (@fiona_godsman for those who know what that means!) and I gamely tweeted into the ether from time to time at #ERBI09, but without a lot of chums. It will be interesting to see if projecting a hashtag page during conference sessions catches on at events like this; and the extent to which it energizes rather than simply distracts from the presentations. It will certainly make them more responsive and engaged (in the same way as prohibiting PowerPoint, or limiting it to 3 slides, as some conferences do). Just some suggestions.

Our panel was focused on personalized medicine and other future developments – an opportunity for the kind of general discussion that most sessions did not permit. In my intro I was asked to explain something about the Center for Policy on Emerging Technologies (C-PET), and it set the context for the kind of interdisciplinary and wide-ranging discussion that should intersperse all our focused and necessarily narrow engagement with technical, commercial, ethical, and other issues. The reason is simple: the speed of change is so great that no-one can any longer be merely a specialist. Which is not to say that we can be merely generalists either. Perhaps a good model of an achievable aim is specialism at one level or another, plus excellent peripheral vision. So industry people can talk to finance people and policy people and ethics people and technology experts, and have enough overlap that they are really communicating. “Personalized medicine,” whether it is the Holy Grail or not, is a great example of the kind of issue that will yield only to that kind of discussion. Part of the value of panels like this at high-level professional/business conferences is to encourage those in attendance to “get peripheral” in the way they think. Peripherality, as it were, is no longer peripheral; it emerges as a key driver of success – especially when times are a-changing and paradigms a-fracturing. From the discussions I had with dozens of ERBI-ites, things don’t look bad at all from this perspective. The somewhat diminished attendance at our session owed as much to its timing (late afternoon) as its topic, though in general peripherality is not valued as it should be. (In the academic world, the equivalent attitude – spouted in response to almost any collaborative or novel project – is “how will this help me get tenure?”)

So I emphasized the importance of anticipatory discussion; of cross-sectoral discussion; and of mainstreaming the discussion since the more potentially transformative the question (and biotech, neuro, AI and other items we touched on are vastly so) the better prepared everyone has to be – even if we see “everyone” in terms only of markets and regulatory environments. Both stem ultimately from people’s understanding and tolerances. As it happens, greater “peripherality” among experts and leaders helps us all learn the language in which we can engage the people out there – not just the people in here – and develop a common grammar.

Our three expert panelists showed how good experts can get be at communicating across the lines. Barbara Sahakian, Professor of Clinical Neurophysiology at Cambridge and a leader in her field, set the pace by summing up her own research on diagnosing dementia and related themes. She pointed out what enormous sums could be saved if therapies could put off the onset of Alzheimer’s by even one year. Kieran Breen, former pharmacy lecturer at Dundee and now R and D Director of the Parkinson’s Disease Society, offered a patient’s-eye view, and reviewed many aspects of the prospect of personalized medicine (personal medical plans, the 5% of inherited factors, stem cells, gene therapy, neuro implants). Harald Schmidt, Assistant Director of the Nuffield Council on Bioethics – the UK’s de facto national bioethics body – reviewed their extensive work on the implications of the paradigm shift towards personalization – including the marketing of products to patients.

In discussion this all went a little further. What fundamental shifts in healthcare delivery might result? How do we cope with hyped expectations, with growing public enthusiasm for “cures” that may prove much harder to deliver than they believe? with threats to the public funding of science (and healthcare) in the unfolding economic climate? with broader issues such as intellectual property and developing world pressure for resource equity? As with all the best discussions, it ended with hands still in the air.

So thank you, ERBI, for the invitation, and to ERBI’s new leader Harriet Fear, whose debut event went swimmingly. Let’s keep encouraging peripheral vision to power discussion across sectors, and long-term strategic reflection in a context in which the next quarter and the next funding tranche tend to focus the mind too wonderfully. If all the talk about the “biotech” century” and technological convergence and exponential improvements in health is more than dubious hype and rhetoric, that’s the only way to go.

Tech Policy Central‘s annual Summit this past week in San Mateo brought together luminaries from several worlds. In three packed days of panels, discussion flowed widely and expertly across fields from IP to broadband access to the haunting problem of the perceived lack of sympathetic understanding of the federal government for the tech community. Highlights were tweeted as we went along (#tps09). One such: that when President Obama handed the British Queen an iPod, he was probably breaking both the TOS and US copyright law. Another: that when you write an email, during its lifecycle it goes through probably eight different sets of legal status. Another: one speaker reeled off a list of ways in which the Obama administration, deemed to be far the most connected with tech leaders the US has known, is challenging its interests – from anti-trust to offshore earnings.

I was impressed – especially with the quality of the panelists. If representation from Washington was not at quite the highest levels, this was no great surprise. And it neatly illustrated the disconnect that ran through much of the discussion and that is one of the key reasons we are building C-PET.

TPS’s agenda was generally focused on the present and the near-term future -the cultural and legislative gaps between the feds and the Valley. Yet this current failure is a taproot of the key strategic issue around which C-PET is being formed – the fundamental lack of high-level policy interest in the future impact of emerging technologies. If the current situation were healthier, the question of the future would be simpler to address. Which is one reason why the current gaps, and TPS’s efforts to bridge them, are so important. Of course, there are others: we sorely need a vibrant and coherent address to such issues of privacy and IP in the context of current and emerging technologies.

Perhaps the most disappointing part of the program lay in the panels that were intended to touch on the Great Gap. Not that panelists lacked smarts and articulate reflection. But they seemed either to have despaired of change, or to believe that it would come about by additive efforts. One preached that we needed to do “more and more and more” to get the issues in front of our legislators. And one of the federal speakers himself made a plea for more lobbying.

This ain’t gonna cut it. And my disappointment lay in the fact that no-one – at least no-one when I was listening, as I sat and tweeted and emailed and did all the distracted things we now do at conferences in technoworld – said simply: this is a strategic issue; indeed, a series of strategic issues; they will not be resolved by lobbying and getting a smattering of people from the Valley into government; we face a vast question and need to come up with some quite fresh answers.

Here’s my take. Strategic issues include:

1. We are in the middle of a tech-driven Kulturkampf. A cultural revolution. Legislative process and political leadership in general (even the Blackberry-toting President) are the creatures of a way of understanding the world, and the relations between technology and the world, that were laid down (at best) in the days of Vannevar Bush and Eisenhower. Our approach to IP of course goes back much further, and has barely adapted (as illustrated by current lawsuits against Myriad Genetics on the breast-cancer gene, and Google on their use of trademarks as ad triggers). And the protection of privacy (as noted above) is a bizarre affair. Think Gestalt. Think tectonic shifts. Think Thomas_Kuhn.

2. It is not simply that things are changing. Our mechanisms to manage this change are very weak. The Science Committee of the House of Representatives is not exactly the capstone committee; the place where aspiring members want to top out their careers. Its members and staff have done a fine job. But they are not the leaders of opinion, even Hill opinion. It remains to be seen whether the White House Office of Science and Technology Policy (OSTP) will take more initiative in this administration than the last (and I expect it will), but most people, including (to my surprise; but on reflection perhaps not) assorted attendees at TPS, did not know what it was. The demise of the Office of Technology Assessment (OTA), which offered a non-partisan view of the implications of new technologies, goes back to Newt Gingrich’s reforms of Congress. If OTA were around today (and, interestingly, Hillary Clinton advocated its reinstatement during her campaign) it would have a lot on its docket. (And while some tech advocates assume that such assessments will always be negative, savvy investors – who know what GMO stands for – take a broader view of the value of social critique. We need many things – not just an Office of Technology Enthusiasm.) And when did the Washington Post, which has a lot to do with the federal agenda (setting and reflecting) last lead with a tech story (aside, perhaps, from stem cells, which should be filed under politics rather than tech).

3. Geography. If a key goal of TPS is to seek to build the Bridge to Somewhere (aka DC), why is it convened on the wrong coast? The United States has perhaps the most “geographical” government of any nation on the planet (though the phenomenon is characteristic of federal entities). What happens in Mexico may stay in Mexico. What happens in DC is what happens. I’m not making a practical criticism – if TPS09 had been convened in DC it might have garnered some more senior federal panelists, but would have lost maybe two-thirds of its attendees (and no-one in DC expects to pay to go to anything, let alone to have to sit through tree days of it!). Which says something about the reciprocal problem of DC and the Valley. But there’s no doubt about it: out-of-towners and lobbyists don’t cut the mustard. If you want to be taken seriously, strategically seriously, in the Beltway – at least on something other than a narrow money/language/vote issue – you need to hang out in the right zipcode. And it’s an interesting reflection on the subtle impacts of IT that “geographicality” is perhaps even more important now than it was; as it is constantly surprising us.

4. Which raises the question of the commitment of our political class, and the people they represent, to S and T. That’s the Big One. It lies behind the lackadaisical interest in the particulars in tech as such (rather than its ad hoc use) on the part of cultural and political leaders. The general disinterest of the major think tanks in the issues that will ultimately provide the context for all issues. The generally hobbyist treatment meted out by the press in their “technology” sections. And so on.

5. And that in turn brings us to C-PET’s agenda, which of course is more future-focused. The need is not just to bridge into today’s tech policy, but tomorrow’s.

So, thanks to Natalie and Marc and their colleagues. An agenda of profound importance laid bare – importance to entrepreneurs, and citizens, and the United States. We have much work to do.